Company intelligence / Profile preview
Intract Pharma
London, United Kingdomintractpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Intract Pharma specializes in oral drug delivery technologies for targeted release within the gastrointestinal tract. Their proprietary platforms enable oral administration of biopharmaceuticals that would otherwise require injection. One clinic-stage product using their technology has completed Phase III trials with market entry anticipated as of 2019. The company continues to develop additional programs focused on chronic inflammatory and autoimmune conditions
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Oral delivery of biopharmaceuticals (including monoclonal antibodies and complex proteins)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Intract Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intract Pharma.